Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by equities researchers at Robert W. Baird in a note issued to investors on Tuesday, October 17th. They presently have a $101.00 target price on the biotechnology company’s stock. Robert W. Baird’s target price indicates a potential upside of 111.34% from the company’s previous close.
Other research analysts have also issued research reports about the stock. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Nomura restated a “buy” rating and set a $84.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $64.10.
Sarepta Therapeutics (NASDAQ SRPT) opened at 47.79 on Tuesday. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $52.67. The firm’s 50-day moving average price is $48.07 and its 200-day moving average price is $38.37. The company’s market cap is $3.07 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 62.44%. The firm had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the prior year, the firm earned ($0.95) EPS. Analysts expect that Sarepta Therapeutics will post ($1.13) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by Robert W. Baird” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/sarepta-therapeutics-inc-srpt-rating-reiterated-by-robert-w-baird.html.
In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of Sarepta Therapeutics stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.60% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Prentiss Smith & Co. Inc. increased its stake in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in Sarepta Therapeutics in the first quarter valued at $127,000. PNC Financial Services Group Inc. increased its stake in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC bought a new stake in Sarepta Therapeutics in the second quarter valued at $175,000. 65.42% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.